A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises

Inclusion Criteria:

1. Participant has a confirmed diagnosis of SCD (HbSS, HbSC, HbSB0 thalassemia, orHbSB+ thalassemia genotype). Documentation of SCD genotype is required and may be based on documented history oflaboratory testing or confirmed by laboratory testing during Screening.

2. Participant is male or female, ≥ 12 years of age at the time of informed consent.

3. Participant has experienced between 2 and 10 VOCs within the 12 months prior to theScreening Visit as determined by documented medical history. A prior VOC is definedas an acute episode of pain which:

• Has no medically determined cause other than a vaso-occlusive event, and

• Results in a visit to a medical facility (hospital, emergency department,urgent care center, outpatient clinic, or infusion center) or results in aremote contact with a healthcare provider; and

• Requires parenteral narcotic agents, parenteral nonsteroidal anti- inflammatorydrugs (NSAIDs), or an increase in treatment with oral narcotics.

4. Participants receiving erythropoiesis-stimulating agents (ESA, e.g., erythropoietin [EPO]) must be on a stable dose for at least 90 days prior to the Screening Visitand expected to continue with the stabilized regimen throughout the course of thestudy.

5. Participants receiving hydroxyurea (HU), L-glutamine, or voxelotor (Oxbryta®) mustbe on a stable dose for at least 30 days prior to the Screening Visit and expectedto continue with the stabilized regimen throughout the course of the study.

Exclusion Criteria:

1. Participant is receiving regularly scheduled red blood cell (RBC) transfusiontherapy (also termed chronic, prophylactic, or preventative transfusion).

2. Participant is taking or has received crizanlizumab (ADAKVEO®) within 90 days priorto the Screening Visit

3. Participant weighs > 133 kg (292 lbs.).

Other protocol-defined Inclusion/Exclusion may apply.